Bank of New York Mellon Corp Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Bank of New York Mellon Corp boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 764,242 shares of the biopharmaceutical company’s stock after purchasing an additional 92,612 shares during the quarter. Bank of New York Mellon Corp’s holdings in Regeneron Pharmaceuticals were worth $589,896,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of REGN. WPG Advisers LLC grew its position in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. Entrust Financial LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at about $32,000. Caitlin John LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $38,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $618.95 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The firm has a market capitalization of $65.44 billion, a price-to-earnings ratio of 15.08, a price-to-earnings-growth ratio of 1.33 and a beta of 0.25. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $711.47 and a 200 day moving average of $743.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period last year, the firm earned $8.22 earnings per share. The company’s quarterly revenue was up 19.0% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on REGN shares. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a report on Monday, May 18th. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.